Clinical Trial Update: Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating AT-101 in combination with Rituximab for chronic lymphocytic leukemia has completed, assessing safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• AT-101 (gossypol acetic acid)
• Rituximab (rituximab)

Snippet

Sponsor: Ascenta Therapeutics | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED